Sustained release delivery of water soluble bio-molecules and drugs using phosphokipid-coated microcrystals, microdroplets and high-concentration lipsomes

ABSTRACT

The novel uses of the phospholipid-coated microcrystal in the delivery of water-soluble biomolecules such as polypeptides and proteins. The proteins are rendered insoluble by complexation and the resulting material forms the solid core of the phospholipid-coated particle. Alternatively, the proteins, bio-molecules or drugs can be entrapped in water-soluble form between the membranous layers of the coated microcrystal. All types of phospholipid microcrystals can incorporate 5 nm to 10 um diameter iron oxide particles to allow for manipulation by magnetic fields. Water-soluble bio-molecules including proteins, peptides, and drugs can be entrapped and retained with long shelf life in liposomes at high concentrations, provided that the phospholipid concentration is greater than 10% (w/v) such that greater than 50% of the system volume is enclosed within phospholipid membranes. Both the phospholipid-coated microcrystal and the phospholipid-coated microdroplet can be used as vaccine adjuvants.

This is a continuation in part of Ser. No. 514,012 filed Apr. 26, 1990,now U.S. Pat. No. 5,091,188.

This invention relates to additional pharmaceutical uses of thephosphilipid-coated microdroplet (Haynes, U.S. Pat. No. 4,622,219;Haynes, U.S. Pat. No. 4,725,442) now U.S. Pat. No. 5,091,188. Theabove-cited documents described the utility of these compositions ofmatter in the delivery or water insoluble drugs. Both the microdropletand the microcrystal are able to incorporate water-insoluble drugs athigh payload. In the microdroplet, the oil phase is itself a drug ordissolved a drug. In the microcrystal, the core is pure drug incrystalline or solid form. In both cues, the phospholipid coating wasshown to both render the microdroplets or microcrystals stable inaqueous suspension and to provide tissue-compatible, making thepreparations non-irritating.

The present Specification shows that the phospholipid-coatedmicrocrystal is also a useful means of delivery of water-solublebiological molecules The bio-molecule can either be rendered insolubleby complexation or can be entrapped between the phospholipid membranescomprising the lipid coating of the microcrystal. Incorporation ofmagnetized iron oxide particles allows for external manipulation.

The teachings and working examples of the previous Specification for thephospholipid-coated microcrystal showed that when the phospholipdconcentration is in the 10-20% (w/v) range, the majority of the aqueousvolume is enclosed within or between membrane layers. The presentSpecification shows how this property can be useful means ofsustained-release delivery of water-soluble molecules and drugs by usingconcentrated liposomes: Syringability, injectability, greater than 50%capture of the carried/entrapped molecule and extremely long shelf lifeinsensitive to "leakage", can all be achieved at phospholipidconcentrations greater than 10% (w/v).

The present Specification will also show that the phospholipid-coatedmicrodroplet can be used to increase the residence time and antigenicityof water-soluble molecules, membrane fragments and particles in solidliving tissues when it is coinjected with the above. The microcrystalcan also be used as a vaccine adjuvant.

BACKGROUND OF INVENTION

Both the phospholipid-coated microdroplet and the phospholipid-coatedmicrocrystal depend on the membrane-forming and amphipathic propertiesof phospholipids to maintain their structure. As described in theprevious Specification (Haynes, U.S. application Ser. No. 07/514,012 nowU.S. Pat. No. 5,091,188), fatty acids and detergents are alsoamphipathic, but do not form membranes. Phospholipids are the majorbuilding block of biological membranes, and are very tissue compatible.An important and abundant example is lecithin (phosphatidylcholine). Inthe presence of excess water, phospholipids form membranes ofbimolecular thickness. The polar head groups are oriented to the water;the fatty acyl chains form a palisade structure, with their endsabutting in the center of the membrane.

Liposomes, aqueous core vesicles formed from membrane-formingphospholipids such as lecithin, were first described by Bangham,Standish & Watkins (in J. Mol. Biol. 13:238, 1965). Liposomes producedby homogenization are multi-lamellar, with concentric bilayer membranes.Liposomes produced by sonication are small and unilamellar phospholipidvesicles as described by Haung (in Biochem. 8:344, 1969). Liposomes havethe ability to entrap polar and highly-charged molecules in theiraqueous interiors. Publications describing the use of liposomes toentrap and deliver water-soluble drugs appeared in the early andmid-1970's (cf. Gregoriadis: "The Carrier Potential of Liposomes inBiology and Medicine38 , New. England Journal of Medicine 295:704-710,1976) A large number of patents have been granted for entrapment ofwater-soluble drugs and proteins (Papahadjopoulos, U.S. Pat. No.4,078,052, 1978; Schneider, U.S. Pat. No. 4,089,801, 1978; Miller &Djordjevich, U.S. Pat. No. 4,133,874, 1979; Papahadjopoulos et al., U.S.Pat. No. 4,235,871, 1980; Weber et al. U.S. Pat. No. 4,38,052, 1984;Deamer, U.S. Pat. No. 4,515,736, 1985; Jizomoto, U.S. Pat. No.4,762,720, 1988; Farmer & Beissinger, U.S. Pat. No. 4,776,991, 1988;Yagi et al., U.S. Pat. No. 4,756,910, 1988; Lenk et al., U.S. Pat. No.5,030,453 are a small fraction of the available examples). However, mostof these liposome inventions rely on complicated methods of preparation,including dissolution in organic solvents and evaporation, treatmentwith detergents and the like. Furthermore, the intra-vesicular space asdescribed in these publications is always less than 10% of the totalaqueous space. Thus the "stability of the entrapment" is a seriousconsideration since slow permeation of the entrapped molecules while thepreparation is on the shelf will result in 90% of the moleculeseventually being outside of the liposomes, with loss or the intendedbenefit of the encapsulation.

In the course of working with the phospholipid-coated microcrystalsystem, which incorporates phospholipid up to 20% (w/v), it becameapparent to me that injectable, pharmaceutically-acceptable liposomepreparations encapsulating over 50% of a water-soluble drug can be madeby the simple methods of homogenization, sonication or high shear. Atthis concentration the stability of entrapment during storage is not anissue since the probability of molecules diffusing in is equal to theprobability of molecules diffusing out.

In the present invention i propose the incorporation of particles ofiron oxide in the phospholipid-coated microcrystal. The use of ironoxide in pharmaceutical systems has already been described. Widder andSenyei (U.S. Pat. No. 4,345,588, 1982) described the IV injection ofalbumin microspheres consisting of drug, serum albumin and Fe₃ O₄ powderin a ratio of 10:125:36. The albumin is crosslinked by formaldehyde.Particle diameter was 10 un. The phospholipid-coated microcrystaldescribed by me previously (Haynes, U.S. application Ser. No. 07/514,012now U.S. Pat. No. 5,091,188) does not rely on crosslinked albumin.Morris (U.S. Pat. No. 4,331,654, 1982)described a lyophilizedpreparation of <3 um diameter magnetically-localizable microspheresconsisting of a core of magnetite (Fe₃ O₄) coated with a solidifiedmixture of fatty acid and non-ionic detergent, and containing lecithinas a minor constituent. The phospholipid-coated microcrystal describedby me previously (Haynes, U.S. application Ser. No. 07/514,012 now U.S.Pat. No. 5,091,188) does not rely on detergent to suspend the particles.

In this specification I also describe the use of the phospholipid-coatedmicrocrystal and phospholipid-coated microdroplet as vaccine adjuvants.Much use has been made of phospholipids and oils in adjuvant systems,but no published system fits the description of the phospholipid-coatedmicrocrystal or microdroplet. There is a considerable amount ofpublished work on the use of liposomes as adjuvants (Allison &Gregoriadis, U.S. Pat. No. 4,053,585, 1977; Nerome et al., U.S. Pat. No.4,826,687, 1989) and detergent-solublized oils as adjuvants (Gerber,U.S. Pat. No. 4,806,350, 1989). In the cases where phospholipids andoils have been used together, the systems contained detergents orcontained high concentrations of ethylene glycol, propylene glycol orthe like (Cantrell, U.S. Pat. No. 4,806,352, 1989; Cantrell & Rudbach,U.S. Pat. No. 4,803,070, 1989).

DESCRIPTION OF THE INVENTION

My invention provides compositions and procedures for sustained releasedelivery of water-soluble drugs and biomolecules by incorporation intophospholipid-coated microcrystals. Water-soluble bio-molecules caneither be rendered insoluble by complexation and incorporated into thesolid cores of phospholipid-coated microcrystals, or they can beincorporated in water-soluble form by entrapment between the membranelayers. After injection the bio-molecule must traverse the membranelayers before it can escape to the tissue. In the former case it alsomust first dissociate from its insoluble complex. Both of theseprocesses give rise to slow release, such that the injected tissue andthe system as a whole experience lower but sustained concentrations.This can give rise to more useful therapeutic effects of thebio-molecule. The inter-membranous entrapment mechanism is also usefulfor drugs. On the other hand, when the bio-molecule is antigenic and theinjection is intradermal, subcutaneous or intramuscular, the longerresidence time obtained with the microcrystal administration cantranslate into an adjuvant effect. Coinjection of high concentrations ofphospholipid-coated microdroplets also increase the residence time ofinjected molecules and antigenic membrane fragments and virus particlesand increase antibody titer.

Definitions:

The biological molecule (bio-molecule) can be a peptide, a polypeptide,a protein, a complex carbohydrate, a glycoprotein, a lipoprotein, aglycolipid, a hormone, a biological response modifier, deoxyribonucleicacid (DNA), ribonucleic acid (RNA) or any other natural product orproduct of genetic engineering. Also contemplated are supramolecularaggregates or one or more type or bio-molecule as in bacterial membranefragments and viral coat proteins, the major limitation being that theaggregates must have dimensions less than 10 um. The use of lowmolecular weight drugs of defined structure has already been described(Haynes, U.S. application Ser. No. 07/514,012 now U.S. Pat. No.5,091,188). For ease of description in difficult passages, I willsometimes use the term microcrystal when a phospholipid-coatedmicrocrystal or particle of amorphous solid of <10 um diameter ormaximal dimension) is intended.

Methods of Production:

Production is accomplished by appropriate combination of the stepsdescribed in the following subsections. Methods for size reduction canbe categorized as two types: Those involving low shear producing smallerparticles and those creating high shear producing larger particles. Lowshear methods include Waring Blender, "high" and propellerhomogenization and rotating tube and plunger homogenizers. High shearmethods include the French Pressure Cell or "French Press" (SLMInstruments, Urbana Ill.), sonication (Heat Systems Co., Melville, N.Y.)and Microfluidization® (Microfluidics Corp., Newton Mass. 02164). Thelatter, which is described by Mayhew et al. in Biochim. Biophys Acta775:169-174, 1984, is particularly well suited for commercialproduction.

Precipitation of Bio-Molecule

This step is necessary for preparations in which the bio-moleculecomprises the solid core of the phospholipid-coated microcrystal. For awater-soluble bio-molecule to remain stable in the preparation it mustbe rendered insoluble. Often the substance is insoluble or takes theform of a paste at 20% (w/v) concentration. It is possible to facilitateprecipitation by lowering the water activity by increasing the glucoseor salt concentration to high values. My experience has shown thatliving tissues tolerate high tonicity in phospholipid-coatedmicrocrystal preparations. High tonicity can also accelerate the releaserate. If the bio-molecule remains soluble at very high concentration, itis often possible to effect precipitation by small changes in pH orionic composition. Precipitation can also be accomplished by adding acationic macromolecule to an anionic protein and vice versa. An exampleis protamine precipitation of heparin. Useful cationic proteins includepolyarginine, polylysine, polyhistidine and many proteins withisoelectric points greater than 8. Useful anionic proteins arepolyglutamic acid, polyaspartic acid and many proteins with isoelectricpoints less than 6. In addition a number of salts can affect solubility.These include: 2-naphthylenesulfonate (napsylate), gluconate,1,1'methylene bis(2-hydroxy-3-naphthalene)-carboxylic acid (pamoate),tolylsulfonate (tosylate), methanesulfonate (mersylate), glucoheptanoate(gluceptate), bitartrate, succinate, acetate, or behenate (anionic formof waxy fatty acid). In choosing fatty acyl anions it is advisable toselect species with either short chain lengths or very long chainlengths, such that the tendency of towards micellarization is minimized.In some cases substitution with bromide, iodide, phosphate or nitratemay be effective. Examples of cationic species include calcium,magnesium or their 1:1 fatty acid salts, and various amines, includingdibenzylethylenediamine (benzathine), N,N' (dihydroabietyl)ethylenediamine (hydrabamine) or polymers such as polylysine. The choice ofthese counterions is made largely on an empirical basis, with stabilityof the derived crystals or solid forms and biological stability beingimportant criteria. Scientific literature describing the method ofpurification of the protein can be useful in this regard. In the casewhere none of the above strategies works to precipitate the bio-moleculeit will be possible to remove it from solution by precipitation with anequal weight mixture of cationic and anionic polypeptides, such aspolyarginine and polyglutamic acid. With sufficient study of the invitro behavior of the phospholipid-coated microcrystals made from anumber of these systems, and with judicious choice of the most promisingexamples, the desired in vivo pharmacokinetics can be approximated.

Size Reduction and Primary Coating:

Two cases must be distinguished: (A) When the insolublized bio-moleculeis to comprise the solid core of the phospholipid-coated microcrystaland (B) when the bio-molecule, in soluble form, is to be entrappedbetween the membrane lamellae, with another pharmacologically-acceptablesolid material comprising the core. In either case the core materialmust be reduced to <10 um or submicron dimensions in an aqueous medium.This can be accomplished by sonication or other treatments involvinghigh shear. Lecithin (or other membrane forming lipid), present duringthe sonication, is itself broken into highly reactive fragments withexposed hydrophobic surfaces. These fragments coat and envelop thesubmicron core material creating a primary coating. A requirement forthis process is that the lecithin and core maternal be present togetherduring the sonication or alternative high-energy dispersing process. Thecommon aspect or all of these preparative methods is that the fatty acylchains of the phospholipid must have direct access to the core materialduring the coating process. In Case B, the bio-molecule in water-solubleform is entrapped within the enveloping layers of the primary coating.It is possible to increase the thickness of the primary coating byadding additional phospholipid to the suspension after sonication orhigh shear, and by suspending this phospholipid by homogenization at lowshear ("high speed homogenizers", propeller homogenizers, Waringblender, or rotating tube and plunger homogenizers).

In my invention, the amphipathic properties of the phospholipid satisfyboth the hydrophilic properties of water and the hydrophobic propertiesof the surface of the core material. Also, the phospholipid membranesurface serves as a stationary barrier to reformation of macroscopiccrystals or solids. A second useful property of the primary coating ismodification of the rate of the dissolution process of the insolublizedbio-molecule. Firstly, the coprecipitants are also entrapped within theprimary coating and the bio-molecule will thus remain in insoluble formuntil these are released. Secondly, the bio-molecules in soluble formwill remain entrapped until the membranes comprising the primary coatingare broken or otherwise disrupted. Possible structural features of thephospholipidmicroerystal interaction have been schematized previously(Haynes, U.S. application Ser. No. 07/514,012 now U.S. Pat. No.5,091,188).

Secondary Coating: Peripheral Phospholipid

In addition to making use of lecithin and other membrane-forming lipidsas a coating and enveloping material, my invention makes novel use ofmembrane-forming lipids as mechanical buffers, organizers of aqueousvolume and retardants of recrystallization of the drug. This is achievedby excess phospholipid in the form of unilamellar and multi-lamellarphospholipid vesicles which form a secondary coating of the suspendedmicrocrystal. Bio-molecules in soluble form will also be entrappedwithin these structures if present during the sonication or high-shearprocess. Unilamellar vesicles are formed as the main byproduct of thesonication and primary coating process. Their retention in thepreparation was found to improve the long-term stability of theformulation. Also, performed multi-lamellar vesicles (made byhomogenization) or uni-lamellar vesicles can be added to the preparationto improve in stability or pharmacokinetics. Preformed vesicles can bemade in the presence of the bio-molecule to entrap it in the aqueousvolume encompassed by their membranes. The secondary coating is looselyattached to the coated microcrystal. Peripheral vesicles associate withand dissociate continuously In the preparation. Previous experimentation(Haynes. U.S. application Ser. No. 07/514,012 now U.S. Pat. No.5,091,188) has shown that the secondary coating can be removed byrepeated centrifugation and resuspension of the preparation.

Peripheral vesicles forming a secondary coating stabilize thepreparation. While not wishing to be bound to any particular theory ormode of action, detailed consideration has suggested the followingmechanisms:

They act as volume buffers interposed between the primary-coatedmicrocrystals. The crystalline and microcrystalline drugs are often moredense than the phospholipid which is, in turn, more dense than water.Thus they wall tend to settle under the influence of gravity and willexperience greater long-range interactions (van der Waals attraction)than the other two constituents. The secondary coating increases thedistance of closest approach of the microcrystalline drug cores, therebydecreasing the van der Waals attraction. It is probable that part of thedriving force for the secondary coating is van der Waals attractionbetween the primary-coated microcrystal and the phospholipid vesicle.Phospholipids (notably lecthin) are ideal as the primary and secondarycoating because they are strongly hydrated and engage in well-documentedshort-range repulsive interactions which make them very resistant toaggregation and fusion.

When peripheral phospholipid is present at 20% (w/v), the majority ofthe aqueous volume of the preparation is enclosed within phospholipidmembranes. This serves as a topological barrier to recrystallization ofthe drug In a preparation during long-term storage. Reformed crystalscan not be larger than the diameter of the vesicles or distance betweenthe vesicles. Both distances can be kept small.

Enclosure of the major portion or the aqueous volume by membranousstructures ensures a high degree of the bio-molecule during preparationrenders "leakage" during shelf-life inconsequential, and retards therelease process after injection into a living tissue.

Choice of Pharmacologically-Acceptable Core Material

In Case B, in which the water-soluble bio-molecule or drug is to beentrapped in water-soluble form between the membrane layers, it isnecessary to provide another material comprising the microcrystal(microparticle) core. This can be any pharmacologically-acceptablewater-insoluble substance which should generally have a water solubilityof <5 mg/ml at physiological pH (6.5-7.4). It can be selected from, butis not limited to, paraffin, tristearin, ethyl oleate, cetostearylalcohol, cetyl alcohol, myristy alcohol, stearyl alcohol, petrolatum onbiocompatible polymer. The core material can also be selected fromwater-insoluble drugs, including but not limited to oxytetracycline(antibiotic), phenylbutazone (anti-inflammatory), cyclosporin(immunosuppressant) or an immunostimulating drug. There are many casesin which simultaneous treatment with a drug and bio-molecule isdesirable.

Physical characteristics of the microcrystal preparation:

Sonication or high-shear is most conveniently carried out with the thecore material at concentrations of 5% (w/v) or less and themembrane-forming lipid at 5% or greater. It is also convenient to addfurther core material and to repeat the process. With this method orstep-wise addition, final concentrations of 20% core material can beachieved. The sonication or high-shear process results in a syringablesuspension of coated microcrystals of predominantly sub-microndimensions, with the particles exhibiting Brownian motion. Over a periodof 1-2 days the microcrystals settle creating a distinct zone in whichthe concentration of core material is 20-40% (w/v). The finalconcentration and volume are dependent on the choice of core materialand upon the choice of peripheral phospholipid concentration. In mostpreparations the bottom zone is resuspendable with inversion to give ahomogeneous and syringable suspension, even after a period of months.For preparations in which this was not the case, resuspendability wasobtained by increasing the peripheral phospholipid concentration.

The slow sedimentation process can be used as a means of concentratingthe preparation. Removal of the volume above the sedimentation zoneafter 1-2 days results in preparations in which the core material is at20-40% (w/v). Long-term storage results in no further settling. Thepreparations remain homogeneous, syringable and pharmaceuticallyacceptable for many months. Microscopic examination of thesepreparations reveals distinct micron and sub-micron diameter particlesof core material. The volume between these is almost completely filledwith the primary enveloping layers and by phospholipid vesicles. Thelatter can be conveniently visualized by Nile Red staining. In thisconcentrated form, the microcrystals exhibit only restricted BrownianMotion. Under microscopic observation they are not observed to changeposition in relation to eachother. They vibrate or "dance in place"about their central position. This partial restriction of motion isprobably an important factor in the long-term stability of thepreparation.

Lyophilization

The microcrystal and liposome products can be put into dry form bylyophilization to yield a powder which can be later reconstituted. Thisis useful when the long-term chemical stability of theto-be-encapsulated drug or bio-molecule in an aqueous environment ispoor. The product can also be put into a capsule or be compacted into atablet for oral administration.

Method of Preparation of High Concentration Liposomes

Water-Soluble bio-molecules and drugs can be delivered by liposomes. Mystudies in optimization or the phospholipid-coated microcrystal haveshow that liposomes can be prepared at high concentration (>10% w/v,typically 20% w/v), such that >50% of the aqueous volume is enclosed byliposomal membranes. This constitutes a syringable, injectablepharmaceutical composition for water-soluble, membrane-impermeantpharmacologically-active molecules. Entrapment is accomplished by addingto an aqueous solution of bio-molecule or drug a sample of dry orprehydrated phospholipid to a final concentration of 10-20% (w/v) whilesubjecting to high-speed homogenization, sonication, or high shear (asdescribed above for the microcrystal).

Preparation and Physical Characteristics of the Phospholipid CoatedMicrodroplet Preparation

This information has been given previously (Haynes, U.S. Pat. No.4,725,422, 1988). In use of the microdroplet to decrease the rate ofmigration of a bio-molecule from its site of injection in a solid livingtissue, it is most desirable to make the former with a persistent oil(low water solubility and low volatility), with the oil concentration inthe final product in the 10-20% (w/v) range. This is because occupationand blocking of the interstitial aqueous space or the target tissue isimportant to the mechanism of retardation of migration of thebio-molecule. Oils having this property include vitamin E, otheroil-soluble vitamins, squalene, squalene, triglycerides, fluorocarbons,chlorocarbons, fluorochlorocarbons, volatile anesthetics, isopropylmyristate, benzyl benzoate and other water-insoluble esters, ethers,silicones, oleyl alcohol and other water-insoluble esters or mineraloil.

Modes or Administration of Microcrystal and Microdroplet Formulations:

As noted above, the primary utility of the coated microcrystal is itsinjectability. Applicable injection sites are any living tissue or bodycavity. They include but not limited to intra-venous (IV),intra-arterial (IA), intra-muscular (IM), intra-dermal, sub-cutaneous(Sub-Q), intra-articular, cerebro-spinal, epidural, intra-costal,intra-peritoneal, intra-tumor, intra-bladder intra-lesional,sub-conjunctival, etc. Of particular usefulness are IM and Sub-Qadministration for obtaining sustained release "depot" action. Inaddition, the phospholipid coating and submicron size or the preparationmay prove to have advantages for oral use, both as an aqueous suspensionand as a lyophilized product. Membranous encapsulation should protectproteins from the action of digestive enzymes, and the coated surfaceand mass of the microcrystal may be conducive to trans-epithelialtransport of the bio-molecule in intact form. Similarly), the aqueoussuspension may show advantageous for topical application, andinstillation into the eye or ear. The preparation can deliver drugs bythe inhalation route, in the form of either an aqueous suspension or alyophilized powder.

The above is also applicable to the administration of the bio-moleculeentrapped in phospholipid vesicles at phospholipid concentrationsgreater than 10% (w/v).

For application or bio-molecules or biologicals in water-soluble form byadmixing and coadmimistration with phospholipid-coated microdroplets,intradermal,

Sub-Q and IM injection is the most indicated route.

Rate of release after administration:

The most important determinant of the rate of release of the drug is thechoice of injection site. If the formulation is injected intravenously,the drug or bio-molecule will be released to the system as rapidly as itcrosses the membrane barrier of the microcrystal or liposome. Forwater-soluble drugs and low molecular weight natural products this ratewill be determined by its non-specific permeability. For high molecularweight bio-molecules the process will require breakage or disruption ofthe membrane. This process can be facilitated by making the preparationhypertonic. For cases of very effective entrapment, the whole particlewill be removed from the blood by endo- or phagocytotic processes.

When the microcrystal and liposome formulations are injected at highvolume into a solid tissue such as muscle skin, the net rate of releasecan be exceedingly slow. The particles generally remain in the initialelements or volume created by the injection. These are generallymacroscopic and there is little flow or agitation. Release of thebio-molecule or drug occurs by the same mechanism as discussed for theintravenous case except that diffusion of the released molecule out ofthe injected volume is still slower due to the larger diffusiondistances involved. In the extreme, the release process can requireupwards of 14 days. For high and fixed volumes and drug concentrations,the rate of removal can be increased by incorporation of hypertonicglucose. For preparations with residence times of greater than 7 days,the rate of release is affected by granulocyte activity.

In the case of conjection of water-soluble bio-molecules or drugsadmixed with phospholipid-coated microdroplets, the molecules areessentially free in the interstitial space of the injected solid tissue.In this case the retardation of the rate of diffusion from the tissue ispartially dependent on blockage of the interstitial space by themicrodroplets.

Section of Water-Soluble Bio-Molecule or Drug to be Incorporated:

If the water-soluble bio-molecule is to comprise the solid core of themicrocrystal, it must be possible to render it solid as described above.If the water-soluble bio-molecule or drug is to be entrapped between themembranes of the microcrystal or liposome then it must nor bind themembranes or disrupt them, It is desirable that the molecule have ahalf-time of 30 min. or longer for crossing a single phospholipidmembrane, although some benefit can be gained for drugs with half-timesof crossing as low as approx. 30 sec (e.g. IV infusion of cytotoxicdrugs). It is desirable that the drug be chemically stable in a humidenvironment. Otherwise it may be necessary to produce lyophilized forms.

Selection of the Membrane-Forming Lipids for Coating:

The primary requirement is that the coating lipid be membrane-forming.This is satisfied by all lipids which, in the presence of excess water,make bilayer structures of the type is well-documented for phospholipidvesicles or lipsomes. This requirement is not satisfied by fatty acids,detergents, non-ionic surfactants (e.g. polyethylene glycol) ortriglycerides (vegetable oils, tristearin, "fats"). A secondaryrequirement is that the lipid not have a proclivity for converting intomicellar structures. The excludes phospholipids or short chain length (6or less) or lyso-lecithin (containing a single fatty acyl chain). Highstability of the coating material in membrane form is necessary to keepthe drug material from rearranging into macroscopic crystals. This isone reason why non-ionic surfactants do not work well for my intendedpurpose.

Useful examples of membrane-forming lipids are given below:

CLASS A: Primary phospholipids (usable in pure form) include thefollowing:

Lecithin (phosphatidyl choline)

Sphingomyelin

Synthetic zwitterionic phospholipids or phospholipid analogues

To this class belong all phospholipids which spontaneously formmembranes when water is added. These phospholipids can be used in pureform to produce coated-microcrystals. Of all the phospholipids, lecithinis the most useful example because of its high availability and lowcost.

CLASS B: Phospholipids capable of calcium-dependant aggregation. Thesephospholipids include the following:

Phosphatidic acid

Phosphatidyl serine

Phosphatidyl inositol

Cardiolipin (disphosphatidyl glycerol)

Phosphatidyl glycerol

These lipids carry a negative charge at neutral pH. Preferably thesephospholipids can be mixed with lecithin to obtain negatively-chargedsurfaces which will give repulsion between particles. When introducedinto a medium containing 2 mM calcium (such as blood or interstitial).membranes containing these phospholipids are expected to show elevatedaggregation and higher reactivity with cell membranes. This can beuseful in causing the injected microcrystals to aggregate within thetissue, giving slower release rates. The usefulness of this class islimited by the high cost of these phospholipids, relative to lecithin.

CLASS C: Phosphatidyl ethanolamine promotes aggregation in acalcium-independent manner. It can be used in the pure form to coatmicrocrystals at pH 9. When the pH is brought to 7, as upon injectioninto blood or tissue the membranes become reactive, causing theparticles to aggregate and to attach to cell membranes. This can havethe useful property of slowing the release rate.

CLASS D: Cholesterol and steroids. These can ont be used as a solecoating material: They do not form membranes in the pure state. They canbe added to the lecithin or other coating material to change its surfaceactivity, the "microviscosity" or distensibility of the coating. With asteroid hormone (estrogen, androgen, mineralo- or glucocorticoid), it ispossible to influence the local tissue response to the microcrystals aswell as influencing their physical disposition.

CLASS E: Semi-lipoidal molecules can be incorporated into thephospholipid or glycerol lipid membrane and change the surface activityof the microdroplet. Molecules included in this class are the following:

Stearylamine or other long-chained alkyl amines which can be primary,secondary, tertiary or quaternary substituted. These give themicrocrystal coating a positive charge and make them more reactive withcell membranes. Benzalkonium chloride is an aromatic example which isparticularly useful because it also functions as a preservative againstmicrobiological growth in the preparation.

Fatty acids. These can be incorporated at low concentrations (<0.02gm/gm phospholipid) to alter the phospholipid packing and reactivity.

CLASS F: Membrane-active agents, glycolipids and glycoproteins to modifysurface properties. Examples of membrane-active agents include nystatin,amphotericin B and gramicidin which are surface-active antibiotics.These have been shown to bind to the surfaces of phospholipid membranesand change their permeability. Glycolipids or glycoproteins could beincluded as a means or modifying surface reactivity. Likewise,antibodies can be coupled to membrane constitutents to direct or retainthe microcrystal association with targered cells or tissues.(Glycolipids, glycoproteins, and anti-bodies are classified as"biologicals". They would have to be screened for pyrogenicity,antigenicity etc. before use, and the process of gaining regulatoryapproval for such formulations would be more complex.)

CLASS G: Mono-glycerides.

These are not phospholipids, but they have been shown capable of formingoriented monolayers and bilayers in the presence or decane (Benz et al.Biochim. Biophys. Acta 394:323-334, 1975). They may thus prove have someuse in coating for microcrystals. Examples of these lipids include, butare not limited to, the following:

1-monopalmitoyl-(rac)-glycerol (Monopalmitin)

1-monocaprylol-(rac)-glycerol (Monocaprylin)

1-monooleoyl-(rac)-glycerol (C18:1, cis-9) (Monoolein)

1-monostearyl-(rac)-glycerol (Monostearin)

Commercially Available Membrane-Forming Lipids:

Several forms of lecithin are contemplated. As an example, egg lecithin(Pfanstiehl Laboratories) is used in all of the presented examples. Itis preferred for its low price and low degree of unsaturation. Lecithinis also available from bovine heart. Soy bean lecithin is lessexpensive. It has a higher degree of unsaturation. Several syntheticvarieties of lecithin are available which differ in chain length from 4to 19 carbons (Supelco, Inc.). It is believed that lecithins with chainlengths in the biological range (10-18) are useful in variousapplications. Unsaturated lecithins (dioleoyl, dilinoleoyl; beta oleoyl;alpha-palmito beta oleoyl; alpha palmitoyl beta linoleoyl and alphaoleoyl beta palmitoyl) are also available. Diarachidonyl lecithin(highly unsaturated and a prostaglandin precursor) is also available.

Phosphatidic acid is available from egg or as synthetic compounds(dimyristoyl, dipalmitoyl or distearoyl, Calbiochem). Bovinephosphatidyl senna is available (Supelco or Calbiochem).

Phosphatidyl inositol is available from plant (Supelco) or bovine(Calbiochem) sources. Cardiolipin is available (Supelco) from bovine orbacterial sources. Phosphatidyl glycerol is available from bacterial(Supelco) cources or as synthetic compounds (dimyristoyl or dipalmitoyl;Calbiochem).

Phosphatidyl ethanolamine is available as egg, bacterial, bovine orplasmalogan (Supelco) or as synthetic compounds diotadecanoyl anddioleoyl analogues and dihexadecyl, dilauryl, dimyristoyl anddipalmitoyl (Supelco and Calbiochem).

Monoglycerides are available from Sigma Chemcial Co.(1-monopalmitoyl-(rac)-glycerol, monopalmitin;1-monocaprylol-(rac)-glycerol, monocaprylin;1-monooleoyl-(rac)-glycerol(C18:1, cis-9), monoolein;1-monostearyl-(rac)-glycerol, monostearin).

Other constituents:

It is possible to add other constituents to the microcrystal to increaseits stability or modify its rate of release. For example,pharmacologically-acceptable oils can be added at low weightconcentration to facilitate contact between the microcrystal and thephospholipid or glycerol lipid coating. It is necessary that the type ofoil and iu weight concentration be chosen such that the crystalline drugnot be dissolved by the oil and that the coating by the membrane-forminglipid not be disrupted. These relationships can be determinedempirically. Useful oils include, but are not limited to, vitamin E,isopropyl myristate, benzyl benzoate, oleyl alchohol, mineral oil,squalene and vegetable oil.

It is also possible to "precoat" the microcrystals byphospholipid-compatible, non-antigenic molecules which are solid at 37°C. Examples include paraffin, tristearin, ethyl oleate, cetostearylalcohol, cetyl alcohol, myristyl alcohol, stearyl alcohol andpetrolatum. For example, these materials can be incorporated into theprimary coating by sonication or shear at temperatures above theirmelting points. Stabilization can be achieved by adding lecithin duringthe process is temperature allowed to return to the solidification pointof these material. It is desirable to use low weight concentrations(≦10%) of such that the payload is not degraded, the rate or dissolutionof the drug is not unduly impeded. Also, biodegradability may impose afurther limitation.

Suspending medium:

In the final preparation, the continuous phase is generally water,buffered to a physiologically-acceptable pH and containing aniso-osmotic concentration or sodium chloride, glucose, mannitol or otherosmotic agent. In certain applications involving intra-muscularinjection of large volumes or microcrystals at high concentration. it isusefjul to increase the osmolarity of the medium (e.g. glucoseconcentration) to facilitate the spreading of the material in themuscle. As noted above, this can retard the process of compaction afterintra-muscular injection. Where permissible, viscosity-increasing agentssuch as carboxycellulose can be useful to alter the pharmacokineticsfollowing intra-muscular injection and to decrease the rate orsedimentation of the microcrystals upon storage.

In certain applications it is useful to substitute a polar solvent forwater providing the bio-molecule's solubility in these is less than inwater and that the solvents do not denature the bio-molecule. Examplesor non-aqueous polar solvents which can be used include, but are notlimited to the following: glycerin (water-miscible liquid with adielectric constant or 42.5) and propylene glycol (water-miscible liquidwith a dielectric constant of 32). The coated microcrystals can be madem these media, or can be allowed to sediment into these media. Theprimary requirement is that a substantial portion of the phospholipid orcoating material be in membranous form m this solvent.

Preservatives

Oil-soluble preservatives can be added in process during the primary orcoating phase. These Include, but are not limited to, benzalkoniumchloride, propylparabem, butylparaben, and chlorobutanol. There are alsonumerous water- and oil-soluble agents which can be added to thefinished product as preservatives, including, benzyl alcohol, phenol,sodium benzoate, EDTA, etc.

Weights and measures

All parts and percentages reported herein are by weight (w/w) orweight/volume (w/v) percentage, in which the weight or volume in thedenominator represents the total weight or volume of the system.Concentrations of water soluble constituents in aqueous solution (e.g.glucose) are given in millimolar concentration (mM=millimoles per liter)referred to the volume of water in the system. All temperatures arereported in degrees Celsius. Diameters or dimensions are given inmillimeters (mm=10⁻³ meters), micrometers (um,=10⁻⁶ meters), nanometers(nm=10⁻⁹ meters) or Angstrom units (=0.1 nm). The compositions of theinvention can comprise, consist essentially of or consist of thematerials set forth and the process or method can comprise, consistessentially of or consist or the steps set forth with such materials.

DETAILED DESCRIPTION OF THE INVENTION EXAMPLE 1

Heparin (0.3 gm) is precipitated from aqueous solution by addition of0.3 gm protamine. The insoluble material is washed, resuspended in 3.0ml isotonic glucose, 0.6 ml egg lecithin are added and the mixture issonicated for 20 min to produce lecithin-coated microcrystals (solidmicroparticles) of protamine-heparin complex.

EXAMPLE 2

Tristearin (0.6) and 0.3 gm egg lecithin is added to 3.0 ml of isotonicglucose containing bovine serum albumin (BSA) at 5 mg/mi. The mixture issonicated for 10 min, 0.3 gm egg lecithin are added, and the mixture ishomogenized with a Polytron® apparatus to yield lecithin-coatedtristearin microcrystals (solid microparticles) entrapping 0.5% BSA inwater-soluble form.

EXAMPLE 3

The preparation of Example 3 in which the water-soluble antibioticgentamycin is substituted for BSA. This product constituteslecithin-coated tristearin microcrystals (solid microparticles)entrapping 0.5% gentamycin in water-soluble form.

EXAMPLE 4

The preparation or Example 1 in which both the protamine-heparinprecipitation and the sonication were carried out in the presence of a1% suspension of 10 nm diameter colloidal iron oxide (Fe₃ O₄) particlesin buffered isotonic glucose solution. This constitutes magneticallymanipulatable lecithin-coated microcrystals (solid microparticles) ofprotamine-heparin complex.

EXAMPLE 5

One gm of erythromycin and 1 gm egg lecithin are added to 3 ml or a I%suspension of 10 nm diameter colloidal iron oxide (Fe₃ O₄) particles inbuffered isotonic glucose solution and the mixture is sonicated for 20min. This constitutes magnetically manipulatable lecithin-coatedmicrocrystals or the water-insoluble drug erythromycin.

EXAMPLE 6

Egg lecithin (Pfanstiehl, P-123, Pfanstiehl Laboratories, Waukegan,Ill.) is added to a lightly-buffered isotonic glucose solution to afinal concentration or 20% (w/v) and is dispersed at high speed with aPolytron® apparatus. This results in a syringable dispersion consistingprimarily or <3 um diameter structures as revealed by Coulter N4-MDSubmicron Particle Analyzer and visualization under a light microscope.Experiments with entrapment and exclusion of membrane-impermeant dyessuch as carboxyfluorescein show that greater than 50% of the systemvolume is enclosed within lipid membranes. If the preparation is "doped"with Nile Red as a fluorescent marker for the lipid membrane phase andvisualized under fluoresence microscopy, the suspension appearshomogeneous red at normal concentration, but individual liposomes can beresolved when the preparation is diluted. After sterilization with gammairradiation (1.5 mega-rad) the structures can be shown to remain stablefor many months.

EXAMPLE 7

To a 10% (w/v) aqueous solution of the water-soluble antibioticgentamycin was added egg lecithin to a final concentration of 25% (w/v),and the mixture was homogenized for 10 min with a Polytron® to yieldgentamycin-containing multilamellar liposomes at high concentration.Intra-muscular injection into a dog gave slowed release relative to freegentamycin.

EXAMPLE 8

Vitamin E microdroplets were added to a pseudorabies vaccine to give afinal concentration of 10% (w/v) vitamin E, 3% (w/v) egg lecithin andnormal antigen concentration. The combination was tested in guinea pigs.Antiviral antibody tatar and survival upon challenge with virulentpseudorabies virus were superior to a commercial product havingidentical antigen concentration.

What is claimed is:
 1. A pharmaceutical delivery system for awater-soluble biological molecules consisting essentially of asyringable, injectable aqueous suspension of solid particles of thebio-molecule in a complexed water-insoluble form, the solid particleshaving diameters or maximal dimensions of about 0.05 um to about 10 um,coated with a 0.3 nm to 3.0 um thick layer of a membrane-formingamphipathic lipid which stabilizes the bio-molecules in complexed solidform against coalescence and renders the bio-molecule in solid form,which composition is substantially devoid of uncoated particles.
 2. Apharmaceutical delivery system for a water soluble biological moleculesconsisting essentially of a syringable, injectable aqueous suspension ofsolid particles of the bio-molecule an a complexed water-insoluble form.the solid particles having diameters or maximal dimensions of about 0.05um to about 10 um, coated with a 0.3 nm to 3.0 um thick encapsulatingprimary layer consisting of coating and enveloping layers of amembrane-forming layer of first a membrane-forming amphipathic lipidwhich stabilizes the bio-molecules in complexed solid form againstcoalescence and renders the bio-molecules in complexed solid form, and25 nm to 3.0 um thick secondary layer consisting of secondmembrane-forming amphipathic lipid in vesicular form associated with andsurrounding but not enveloping the lipid-encapsulated solid-formbio-molecules, which composition is substantially devoid of uncoatedparticles.
 3. A pharmaceutical delivery system for water-soluble drugsor biological molecules consisting essentially of a syringable,injectable aqueous suspension of solid particles of apharmacologically-acceptable water-insoluble substance, the solidparticles having diameters or maximal dimensions of bout 0.05 um toabout 10 um, coated with a 0.3 nm to 3.0 um thick layer of amembrane-forming amphipathic lipid which stabilizes the solid particlesof a pharmacologically-acceptable water-insoluble substance againstcoalescence, wherein the water-soluble drug or bio-molecules areentrapped within the layers of membrane-forming lipid.
 4. Apharmaceutical delivery system for a water-soluble drug or biologicalmolecules consisting essentinally of a syringable, injectable aqueoussuspension of solid particles of a pharmacologically-acceptablewater-insoluble substance, the solid particles having diameters ormaximal dimensions of about 0.05 um to about 10 um. coated with a 0.3 nmto 3.0 um thick encapsulating primary layer consisting of coating andenveloping layers of a membrane-forming amphipathic lipid whichstabilizes the pharmacologically-acceptable substance in solid formagainst coalescence, wherein the water-soluble drug or bio-molecules areentrapped within the layers of membrane-forming lipid.
 5. Thecompositions, of claim 1, 2, 3 or 4 wherein the solid particles alsocontain magnetic iron oxide (Fe₃ O₄) particles having diameters maximaldimension of about 5 nm to about 10 um.
 6. A syringable, injectablepharmaceutical composition consisting essentially of an aqueoussuspension of crystals or solid particles of a pharmacologically activewater-insoluble drug substance in solid Form, the solid particles havingdiameters or maximal dimensions of about 0.05 um to about 10 urn, coatedwith a 0.3 nm to 3.0 um thick layer of a membrane-forming amphipathiclipid which stabilizes the drug substance from coalescence and rendersthe drug substance in solid form less irritating to living tissue, whichcomposition contains colloidal iron oxide (Fe₃ O₄) particles of about 5nm to about 10 um diameters or maximal dimensions, which composition issubstantially devoid of uncoated crystals or drug or iron oxideparticles.
 7. A syringable, injectable pharmaceutical compositionconsisting essentially of an aqueous suspension of solid particles of apharmacologically active water-insoluble drug substance in solid form,the crystals or solid particles having diameters or maximal dimensionsof about 0.05 um to about 10 um, coated with a 0.3 nm to 3.0 um thickencapsulating primary layer consisting or coating and enveloping layersof a membrane-forming amphipathic lipid, which stabilizes the drugsubstance from coalescence, and 25 nm to 3.0 um thick secondary layerconsisting or a membrane-forming amphipathic lipid in vesicular formassociated with and surrounding but not enveloping thelipid-encapsulated drug particles, which composition contains colloidaliron oxide (Fe₃ O₄) particles of about 5 nm to about 10 um diameters ormaximal dimensions, which composition is substantially devoid ofuncoated crystals or drug or iron oxide particles.
 8. A solidpharmaceutical composition consisting essentially of the compositions ofclaims 1, 2, 3 or 4, devoid of water which, when water is added, givesan aqueous suspension.
 9. The compositions of claims 1, 2, 3 or 4, inwhich the crystals or particles are wetted with a water-immiscible oilof up to 0.25 gram per gram crystalline or solid substance, tofacilitate contact between the solid substance and the primary ofamphipathic membrane-forming lipid, or to slow the rate of dissolutionof crystals or solid substance or to otherwise modify the rate ofrelease of pharmacologically-active substance.
 10. The composition ofclaim 1, 2, 3 or 4, in which the bio-molecule is an antigen.
 11. Thecomposition of claim 10 in which the antigen is a bacterial membrane ora viral coat fragment. .Iadd.
 12. An orally administrable pharmaceuticalcomposition consisting essentially of a free-flowing aqueous suspensionof solid particles of a pharmacologically active water-insoluble drugsubstance in solid form, the solid particles having diameters of about0.05 μm to about 10 μm, coated with a 0.3 nm to 3.0 μm thick layer of amembrane-forming amphipathic lipid which stabilizes the drug substancefrom coalescence. .Iaddend..Iadd.13. An orally administrablepharmaceutical composition consisting essentially of a free-flowingaqueous suspension of crystals or solid particles of a pharmacologicallyactive water-insoluble drug substance in solid form, the crystals orsolid particles having diameters or maximal dimensions of about 0.05 μmto about 10 μm, coated with a 0.3 nm to 3.0 μm thick encapsulatingprimary layer consisting of coating and enveloping layers of amembrane-forming amphipathic lipid, which stabilizes the drug substancefrom coalescence and a 25 nm to 3.0 μm thick secondary layer consistingof a membrane-forming amphipathic lipid in vesicular form associatedwith and surrounding but not enveloping the lipid-encapsulated drugparticles, which composition is substantially devoid of uncoatedcrystals or particles. .Iaddend..Iadd.14. Composition of claim 12, inwhich the water-insoluble drug substance in a water-soluble drug orbiomolecule is rendered water-insoluble by complexation with apharmaceutically acceptable compound producing a crystalline or solidform. .Iaddend..Iadd.15. Composition of claim 13, in which thewater-insoluble drug substance is a water-soluble drug or biomolecule isrendered water-insoluble by complexation with a pharmaceuticallyacceptable compound producing a crystalline or solid form..Iaddend..Iadd.16. The compositions of claim 12, 13, 14 or 15, whereinthe solid particles comprise a pharmacologically-acceptable substance insolid form and wherein water-soluble drug or biomolecules are entrappedbetween the layers of the membrane-forming amphipathic lipid..Iaddend..Iadd.17. An anhydrous orally administrable pharmaceuticalcomposition in solid form which will produce the free-flowing aqueoussuspensions of claim 12, 13, 14 or 15 when water is added..Iaddend..Iadd.18. A lyophilized orally administrable pharmaceuticalcomposition in solid form prepared by lyophilization of the compositionsof claims 12, 13, 14 or
 15. .Iaddend.